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Abstract 
BACKGROUND: Many randomised control studies showed that percutaneous coronary interventions using 
biodegradable-polymer drug-eluting stents (DES) offer a safe and effective alternative to durable-polymer DES. 
However, not many studies have discussed its use in the setting of acute coronary syndromes. 
AIM: We aim to compare the biodegradable-polymer DES with durable-polymer DES when it comes to reducing 
the incidence of non-ST elevation acute coronary syndrome (NSTEACS) associated with adverse events. 
METHODS: We enrolled 205 patients presenting with NSTEACS and a TIMI risk score ≥ 3 in this study and 
divided them into two groups, group A and group B. Biodegradable-polymer DESs were exclusively used in group 
A, while durable-polymer DESs were used in group B. Major adverse events were reported in both groups during 
the hospital stay and patients were followed-up for 1 year. 
RESULTS: In our patients, we intervened on 390 diseased segments in a total of 360 vessels. After intervention, 
TIMI 0 was achieved in 0.97%, TIMI 1 in 1.46%, TIMI 2 in 2.45%, and TIMI 3 in 95.12% of the treated segments 
(P-value= 0.677). We implanted 121 biodegradable-polymer DESs and 146 durable-polymer DESs. Clinical 
success was achieved in 95.12% of our cases. We had 55 patients who needed repeated coronary angiography 
within 1 year (15 patients treated with biodegradable-polymer DES and 24 patients treated with durable-polymer 
DES). Eighteen patients experienced angina pains (8 patients treated with biodegradable-polymer DES and 10 
patients treated with durable-polymer DES). Only 5 patients needed TLR (2 patients treated with biodegradable-
polymer DES and 3 patients treated with durable -polymer DES) (P-value = 0.591), three of them had a 
myocardial infarction with documented angiographic evidence of significant in-stent restenosis (1 patient treated 
with biodegradable-polymer DES and 2 patients treated with durable-polymer DESs). 
CONCLUSION: Biodegradable-polymer DES represents a comparable alternative to durable-polymer DES in the 
setting of acute coronary syndromes. 
 
 
 
 
 
Introduction 
 
Patients with non-ST segment elevation acute 
coronary syndromes (NSTEACS), including unstable 
angina (UA) and non-ST segment elevation 
myocardial infarction (NSTEMI), have a high risk for 
death and cardiac ischemic events [1].  
Percutaneous coronary intervention (PCI) in 
these cases can result in three major complications; 
namely, acute vessel closure, subacute vessel closure 
and late vessel stenosis. Continuous improvements to 
the stenting technique and stent designs were made 
and resulted in a reduction in the incidence of these 
complications [2].  
Although drug-eluting stents (DES) use has 
resulted in lesser revascularisations, when compared 
to bare metal stents, owing to their strong suppression 
of neointimal hyperplasia [3], [4], their implantation 
leaves the stent with a durable-polymer coating. This 
polymer has been implicated as a potential cause for 
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a chronic inflammatory response that leads to stent 
thrombosis [5], [6].  
Biodegradable polymer-based DES averts 
stent thrombosis by leaving a stent that will have the 
same bare metal lining as a bare metal stent. This 
may result in an improved long-term clinical outcome 
of coronary stenting. Biodegradable polymer-based 
DES has been established as a safe and effective 
alternative to durable polymer-based stent platforms 
as evidenced in several randomised clinical trials [7], 
[8]. Also, an optical coherence tomography study 
showed improved healing of the stented coronary 
artery after implanting a biodegradable-polymer DES 
in comparison to durable-polymer sirolimus-eluting 
stents (SES) at 9 months [9].  
In our study, we aim to assess the role of 
biodegradable-polymer DES in decreasing the 
incidence of major adverse cardiac events (MACE) 
compared to durable-polymer DES in patients with 
NSTEACS. 
 
 
Material and Methods 
 
We enrolled 205 NSTEACS patients from 
amongst all patients admitted to the Cairo University 
Critical Care Medicine Department during the period 
from January 2015 to January 2017. We followed up 
those patients for 1 year clinically, via telephone calls, 
and directly in our outpatient clinics. The follow-up 
angiographies were done earlier in patients who 
experienced ischemic symptoms or signs before the 
end of their follow-up duration. 
Patients enrolled in this study were all 18 
years of age or older. Also, they had coronary lesions 
that were narrowed by more than 60%. They were 
indicated for PCI using DES as per the 
ACC/AHA/SCAI and ESC/EACTS guidelines or the 
clinical judgment of the treating interventionists [10], 
[11]. All participants were randomly assigned to one of 
two treatment groups, group A and group B. Group A 
received PCI using biodegradable-polymer DES 
“BIOTRONIK-Orsiro® Hybrid drug-eluting Stent or 
Terumo Nobori®-Drug eluting stent”, while group B 
received PCI using durable-polymer DES “Medtronic 
Resolute Integrity® Drug-Eluting Coronary Stent or 
Boston scientific The PROMUS Element ®drug eluting 
stent”. In our study, we excluded NSTEACS patients 
with: low TIMI risk score (< 3) [12]
 
who were subjected 
to conservative strategy, marked impairment of LV 
systolic function (LVEF < 30%), cardiogenic shock 
(Killip class IV) [13],
 
contraindication to the use of 
antiplatelet and anticoagulation (aspirin, clopidogrel) 
or heparin therapy e.g. active peptic ulcer in addition 
to patients who co-presented with significant external 
or internal bleeding and those who had severe 
thrombocytopenia (platelet count < 50,000/cmm). 
All of the enrolled patients were admitted to 
our ICU and subjected to full medical history taking, 
demographic characterization, thorough clinical 
examination (general and cardiac examinations), a 
serial twelve-lead ECG, echocardiographic 
examination in addition to routine laboratory 
investigations, including repeated sets of cardiac 
enzymes and troponin, serum creatinine, complete 
blood picture, coagulation profile, and viral hepatitis 
markers. Each patient was given a TIMI score [14]. 
Following PCI, all patients were re-evaluated 
clinically by re-analysing their symptoms, performing a 
careful cardiac examination, acquiring serial 12-lead 
ECGs to detect any dynamic changes or cardiac 
arrhythmias, and ordering follow-up cardiac enzymes 
and troponin whenever it was necessary. 
After receiving the acute care in the ICU, 
patients were then discharged and followed up to 
detect the incidence of any of our primary endpoints 
which constituted the major adverse cardiac events 
(MACE); namely, recurrent angina pectoris, post-
infarction angina, new or recurrent myocardial 
infarction, target lesion revascularization (TLR), target 
vessel revascularization (TVR), left ventricular 
dysfunction, cardiac arrhythmias, and cardiac death. 
Furthermore, patients who did not develop 
any of our primary endpoints during the1-year follow-
up duration were subjected to a follow-up diagnostic 
coronary angiography at the end of that year if the 
patient consented. 
The follow-up coronary angiography views 
were evaluated using quantitative coronary 
angiography (QCA) with edge detection method to 
evaluate the coronary lesions. Minimal luminal 
diameter (MLD), reference vessel diameter (RVD), per 
cent diameter stenosis (%DS), acute gain, late loss, 
and late loss index were estimated. 
The study was approved by the ethical 
committee of the Critical Care Department, Cairo 
University. All the participants agreed to sign a written 
informed consent. 
 
 
Results  
 
A total number of 205 patients were enrolled 
in this study. It included 141 males (68.6%) and 64 
females (31.4%) with a mean age of 57.4 ± 10.2 
years. The average length of stay was 2.7 ± 0.8 days. 
In this study, 100 patients received 
biodegradable polymer-based DES (48.7%), while 
105 patients received durable polymer-based DES 
(51.30%). 
There was no statistical significance between 
the biodegradable-polymer DES and durable-polymer 
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DES groups concerning the risk (Figure 1). 
 
Figure 1: Risk factors for CAD, illustrated by the frequency 
 
There were 390 targeted segments in 360 
vessels in our patients with stenosis percentage of ≥ 
60% (Table 1). 
Table 1: Number of vessels, recorded in our registry, classified 
according to PCI procedure and outcome 
 
Biodegradable polymer 
DES 
Durable polymer 
DES P value 
No % No % 
Single vessel disease 72  72% 85  80.9% 
0.599 
Two vessel disease 28   28%  20  19.1% 
 
 
Long/calcific lesions 
Prevalence of long lesions (≥ 20mm) was 
66.1% in our study. There was no significant 
difference in the prevalence of long/calcific lesions 
between both groups (67.2% for biodegradable-
polymer DES group versus 61.8% for durable-polymer 
DES group, P-value = 0.357). 
Prevalence of calcific lesions was 7.0% in our 
study, (2.2% for biodegradable-polymer DES group 
versus 8.6% for durable-polymer DES group, P-value 
= 0.203). 
 
TIMI flow classification 
Reviewing TIMI flow classification for treated 
lesions before PCI, TIMI 0 was present in 7 patients 
(3.4%), TIMI 1 in 5 patients (2.4%), TIMI 2 in 92 
patients (44.9%), and TIMI 3 in 101 patients (49.3 %) 
(Table 2). 
Table 2: TIMI flow classification patterns among PCI 
procedures 
TIMI flow  
Biodegradable polymer DES Durable polymer DES 
P value 
No % No % 
TIMI 0 3  (2.3%) 4  (4.3%) 
0.677 
TIMI 1 3  (2.3%) 2  (3.4%) 
TIMI 2 43  (44.3%) 49  (44.4%) 
TIMI 3 51  (51.1%) 50  (47.9%) 
 
 
 
PCI procedure details 
A. PCI procedure data 
In our study, there were 390 segments 
reported. One hundred and sixty-eight patients (82%) 
had complete revascularisation, while 37 patients 
(18%) had incomplete revascularisation. There was 
no significant difference between both groups (81.9% 
for biodegradable-polymer DES group vs 82.4% for 
durable-polymer DES group, P-value = 0.589). Stent 
length, diameter and inflating pressures are shown in 
Table 3. 
Table 3: Stent length, diameter and pressure 
 
Biodegradable polymer DES 
Durable polymer 
DES 
P value 
Stent length (mm) 26.6 ± 7.4 26.2 ± 8.0 0.699 
Stent diameter (mm) 3.4 ± 0.4 3.4 ± 0.5 0.542 
Pressure (atm) 14.2 ± 1.7 14.7 ± 2.6 0.237 
 
TIMI 0, TIMI 1, TIMI 2, and TIMI 3 were 
achieved in 0.97%, 1.46%, 2.45%, and 95.12% of the 
treated segments, respectively. There was no 
significant difference between both groups. 
For the biodegradable-polymer DES group, 
121 stents were implanted, while for the durable 
polymer DES group, 146 stents were implanted 
(Figure 2). 
 
Figure 2: Stent frequency 
 
 
B. Procedural complications: 
The angiographic success of PCI procedure: 
Restoring TIMI flow III after the PCI procedure 
was achieved in 95.12% of the treated segments in 
our study. 
Angiographic complications, irrelevant to post-
PCI TIMI flow pattern, occurred in 10 patients (4.9%). 
These complications were acute in-stent thrombosis, 
no-reflow phenomenon, and coronary dissection. 
Three of the patients who suffered from coronary 
dissection were complicated by the no-reflow 
phenomenon (Table 4). 
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Table 4: Detailed procedural complications, according to PCI 
procedures 
 Biodegradable polymer DES Durable polymer DES P value 
N % N % 
Acute stent closure 0 0.0 1 0.9 0.561 
No reflow 1 1 2 1.9 0.598 
Coronary dissection 2 2 3 2.85 0.770 
 
 
C. Clinical Success of PCI procedure and 
IN-Hospital MACE: 
It was defined as accomplishing PCI 
procedure with no in-hospital MACE (death, target 
lesion revascularisation, myocardial infarction, LV 
dysfunction, major bleeding, new or worsening renal 
impairment). Clinical success was achieved in 95.12% 
of the cases (Table 5). 
Table 5: MACE In-hospital details 
In-hospital MACE Biodegradable polymer DES Durable polymer DES P value 
N % N % 
Mortality 0 0.0 1 0.9 0.711 
TLR 2 2 1 0.9 0.577 
Myocardial infarction 1 1 1 0.9 0.680 
LV dysfunction 3 3 4 3.8 0.549 
 
Follow-Up data and 1-year MACE: 
Fifty-five patients consented to have repeated 
coronary angiography within 1 year of their initial 
coronary angiography (23 patients treated with 
biodegradable-polymer DES and 32 patients treated 
with durable-polymer DES). Eighteen of these patients 
experienced angina pains for which they were 
examined thoroughly (8 patients treated with 
biodegradable-polymer DES and 10 patients treated 
with durable-polymer DES). Only five patients needed 
TLR (2 patients with biodegradable-polymer DES and 
3 patients treated with durable-polymer DES). Three 
of them had a myocardial infarction with documented 
angiographic evidence of significant in-stent 
restenosis (1 patient treated with biodegradable-
polymer DES and 2 patients treated with durable 
polymer DES) (Table 6). 
 
 
Discussion 
 
In this study, we enrolled 205 ACS patients. 
One hundred of them, who had a total of 121 lesions, 
were treated with biodegradable-polymer drug-eluting 
stents (BP-DES). The other 105 patients, who had a 
total of 146 lesions, were treated with durable-polymer 
drug-eluting stents (DP-DES). The differences 
between the two groups were insignificant as regards 
angiographic findings and other characteristics. This 
study clearly shows that the 1-year clinical outcomes 
after BP-DES implantation are comparable to those of 
the standard DP-DES implantation. Both stent types 
were associated with a low incidence of target lesion 
failure (TLF) and MACE, indicating their safety and 
efficiency.  
The incidence of in-hospital complications, 
including acute myocardial infarction, need for target 
lesion revascularisation, urgent referral to CABG and 
death, was very low in both groups. Moreover, the 
difference in the incidence of those complications was 
not statistically significant between the two different 
treatment arms (P = 0.725). Although the results of 1-
year follow up for both patient groups were not 
significantly different, 7 patients were reported in 
“follow-up MACE”. Incident mortality was 1% in each 
group (1 patient treated with biodegradable-polymer 
DES and 1 patient treated with durable-polymer DES) 
(P = 0.627). In all of our patients, five patients needed 
TLR (2 patients treated with biodegradable-polymer 
DES and 3 patients treated with durable-polymer 
DES) (P = 0.591). 
Our results agree with Windecker, S. et al., 
results [8]. In their study, they compared the 
biodegradable-polymer (with an ultrathin strut) 
sirolimus-eluting stent (Orsiro, O-SES) to the durable-
polymer Xience Prime everolimus-eluting stent (X-
EES). In their multicenter non-inferiority study which 
included a total of 452 patients who were randomly 
assigned to treatment with either O-SES (298 
patients, 332 lesions) or X-EES (154 patients, 173 
lesions), the patients’ ratio was 2:1, respectively. The 
primary endpoint was an in-stent late loss at 9 
months. O-SES was found to be non-inferior to X-
EES. Clinical outcomes of both patients’ groups were 
similar in rates of target-lesion failure at 1 year (O-
SES 6.5% versus X-EES 8.0%; hazard ratio = 0.82; 
95% confidence interval, 0.40-1.68; log-rank test: P = 
0.58) with no reported cases of stent thrombosis. 
They concluded that the biodegradable polymer-
based O-SES was not inferior to the durable polymer-
based X-EES at their specified endpoint. Clinical 
event rates were comparable with no cases of stent 
thrombosis reported till 1 year of follow-up [14].
 
Moreover, our results concur with Jinnouchi, 
H. et al., results [15]. In a retrospective analysis, they 
studied a total of 1,132 patients who were treated with 
either Biolimus-eluting stents BES (612 patients) or 
cobalt chromium everolimus-eluting stents EES (520 
patients) for a small-vessel disease (stent size 2.5 
mm). They assessed the 2-year cumulative incidence 
of major adverse cardiovascular events (MACE), 
defined as a composite of cardiac death, myocardial 
infarction (MI), definite stent thrombosis (ST), and 
clinically driven target lesion revascularisation (CD-
TLR). The 2-year cumulative incidence of MACE was 
similar in both groups (12.1% vs 11.8%, P = 0.77). 
The cumulative incidence of cardiac death, CD-TLR, 
and definite ST were also not significantly different 
between the two groups (3.2% vs. 3.6%, P = 0.78; 
8.3% vs. 8.4%, P = 1.00; 0.33% vs. 0.21%, P = 0.66, 
respectively). They concluded that the 2-year clinical 
outcomes of BES are similar to those of CoCr-EES 
when used in small vessel lesions. Thus, in their 
analysis, the use of BES was found to be acceptable 
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for small coronary artery lesions [15].
 
 
Our results did not agree with Stefanini, G.G. 
et al. results. They compared long-term outcomes in 
patients treated with biodegradable-polymer DES vs 
those treated with durable-polymer sirolimus-eluting 
stents (SES). They pooled individual patient data from 
large-scale multicentre randomised clinical trials 
comparing biodegradable-polymer DES with durable-
polymer SES and assessed clinical outcomes during a 
follow-up period of 4 years [16]. The efficacy endpoint 
of interest was target lesion revascularisation, and the 
safety endpoint of interest was definite stent 
thrombosis. Out of 4062 patients included in the 
present analysis, 2358 patients were randomly 
assigned to treatment with biodegradable-polymer 
DES (sirolimus-eluting, n = 1501; biolimus-eluting, n= 
857), while 1704 patients were assigned to treatment 
with durable-polymer SES. No heterogeneity across 
the trials was observed in analyses of the primary and 
secondary endpoints. During the 4 years of follow-up, 
the risk of target lesion revascularisation was 
significantly lower among patients treated with 
biodegradable-polymer DES than among those 
treated with durable polymer SES (hazard ratio 0.82, 
95% CI 0.68-0.98, P = 0.029). Also, the risk of stent 
thrombosis was significantly reduced among patients 
treated with biodegradable-polymer DES vs those 
treated with durable-polymer SES (hazard ratio 0.56, 
95% CI 0.35-0.90, P = 0.015). In a landmark analysis 
between 1 and 4 years, the incidence of myocardial 
infarction was lower for patients treated with 
biodegradable-polymer DES than for those treated 
with durable polymer SES (hazard ratio 0.59, 95% CI 
0.73-0.95, P = 0.031). Thus, they concluded that the 
use of biodegradable-polymer DES had offered 
superior safety and efficacy compared to durable 
polymer SES throughout a 4-year follow up period 
[18]. The difference between our results and their 
results may be attributed to the larger number of 
patients enrolled in their study in addition to 
comparing the BP-DES with only one type of DP-DES 
(sirolimus-eluting stents) [16]. 
In conclusion, this study showed that 
biodegradable DES represents a comparable 
alternative to durable DES. We recommend carrying 
out larger studies to reinforce our conclusion. 
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